Cryo-Cell International (NYSEAMERICAN:CCEL) Shares Pass Below Two Hundred Day Moving Average – What’s Next?

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL)’s share price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $4.04 and traded as low as $3.36. Cryo-Cell International shares last traded at $3.40, with a volume of 1,660 shares.

Cryo-Cell International Trading Down 0.3%

The business’s 50-day simple moving average is $3.43 and its two-hundred day simple moving average is $4.03. The company has a market capitalization of $27.40 million, a PE ratio of -10.97 and a beta of 0.59.

Hedge Funds Weigh In On Cryo-Cell International

A hedge fund recently bought a new stake in Cryo-Cell International stock. Susquehanna International Group LLP purchased a new position in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned approximately 0.14% of Cryo-Cell International at the end of the most recent quarter. Institutional investors own 10.44% of the company’s stock.

About Cryo-Cell International

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.